Risk Audit · Cached SEC Snapshot
PHIO Risk Audit — Dilution, Cash Runway, and SEC Filings
Phio Pharmaceuticals Corp.
TL;DR
- MODERATE / CAUTION — No fatal flags, but the structure is not pristine. Read the evidence.
- Doomsday Clock: 51.1mo of cash before the company exhausts its operating runway.
- Dilution Risk: 100 / 100 — heavy active dilution; shareholders likely diluted.
- Dilution Status: High Dilution Risk — Share count changed by +143.1%. No active dilution drivers detected in latest filing.
Doomsday Clock
51.1mo
Company runs out of cash in 51.1 months
Dilution Risk
100 / 100
High dilution — shareholders likely diluted
C
Stockteller Grade
Altman Z: -12.03 (Z)
Gravity Playbook · Mathematical Stress Test
AUTH
Dilution Authorization
The company has an active S-3 shelf registration. Current mechanics indicate the company is authorized to dilute up to 143.13% annually, but is not actively utilizing this authorization.
BURN
Cash Burn Rate
Based on current cash and burn rate, the company's cash runway is mathematically depleted in approximately 51 months.
COMPLIANCE
Nasdaq Compliance
Nasdaq requires a $1.00 minimum bid. Historical precedent for companies with this profile involves structural actions such as reverse splits to maintain listing compliance.
Mechanical analysis only. Not financial advice. Statements describe mathematical conditions and historical precedent, not predictions or recommendations for this security.
Educational analysis only. Not financial advice. The Risk Audit is a quantitative framework derived from publicly available SEC filings and may contain inaccuracies. AI systems are fallible. Always verify against the source filings on
SEC EDGAR
and consult a licensed advisor before making investment decisions.